Spravato treatment involves more than administering a nasal spray and waiting for symptoms to improve. The period after each session can be an important part of the overall treatment experience. Patients may notice temporary changes in perception, alertness, or emotions after administration, making supervised observation and thoughtful follow-up essential.
Understanding this integration period can help patients know what to expect and how it fits into a broader approach to depression treatment.
The term “integration period” can describe the time after a Spravato session when patients process their treatment experience while the immediate effects of esketamine gradually wear off. Spravato is administered under direct supervision, and patients are monitored for at least two hours afterward.
During this period, patients may experience sedation, dissociation, dizziness, or temporary changes in attention and thinking. The clinical team monitors the patient’s condition and determines when it is appropriate to leave the treatment setting.
Integration is not a separate medication or FDA-defined treatment phase. Rather, it can be understood as the recovery and follow-up process surrounding a Spravato session.
Spravato can temporarily affect awareness, judgment, coordination, and alertness. The FDA therefore requires observation after administration, including monitoring of respiratory status and blood pressure as clinically appropriate.
The observation period allows healthcare professionals to monitor how a patient responds as the immediate effects decrease. It also provides an opportunity to communicate any discomfort, unusual sensations, or concerns.
Patients should not treat the end of the observation period as permission to immediately resume every normal activity. Spravato can continue to affect alertness after leaving the clinic.
Every treatment experience is different. Some patients may feel sleepy or physically relaxed, while others may experience dissociation or changes in their perception of their surroundings.
These effects can feel unusual, particularly during an initial session. Understanding that temporary changes can occur may help patients approach them with less uncertainty.
Patients should tell their healthcare provider if they experience significant dizziness, nausea, anxiety, changes in breathing, or other concerning symptoms. The clinical team can determine whether additional monitoring or evaluation is necessary.
A Spravato session is part of a larger treatment plan rather than an isolated event. Providers monitor symptoms over time and consider how the patient is responding across multiple sessions.
At Scottsdale TMS & Spravato, Spravato may be incorporated into broader psychiatric care that can include medication management, psychotherapy, TMS, and other appropriate services. This allows treatment decisions to consider the patient’s overall mental health rather than focusing only on an individual session.
Our Team can discuss changes in mood, treatment response, side effects, and questions that arise between sessions. Keeping providers informed can help them evaluate whether the current treatment approach remains appropriate.
Planning for the hours following treatment is an important part of integration. Patients should arrange transportation because they should not drive themselves after receiving Spravato.
The FDA advises patients not to drive or operate machinery until the day after treatment following a restful sleep because of potential impairment in attention, judgment, thinking, and coordination.
Allowing yourself time to rest can make the transition home more comfortable. You can also write down questions, observations, or changes you notice so you can discuss them during your next appointment.
Psychotherapy may complement psychiatric treatment by providing a structured setting to explore thoughts, emotions, behaviors, and ongoing challenges. When appropriate, therapy can be incorporated into a broader depression treatment plan.
However, patients should not assume that Spravato automatically produces a specific psychological experience that needs to be interpreted. Responses vary, and any emotional or perceptual changes should be discussed with qualified providers when they are concerning or difficult to understand.
Dr. Michael Vines can evaluate treatment progress and help determine how Spravato fits within an individual’s broader mental health care.
The Spravato integration period is best understood as the recovery, observation, and follow-up surrounding treatment rather than a separate medication phase. Supervised monitoring allows providers to assess immediate effects, while follow-up helps evaluate symptoms and treatment response over time.
Patients can support this process by arranging transportation, allowing time for recovery, communicating side effects, and keeping track of questions or changes between appointments. Scottsdale TMS & Spravato provides supervised Spravato care within an individualized approach to depression treatment, helping patients navigate each stage of their treatment experience.
Dr. Vines has practiced psychiatry in Arizona for for over 25 years and has experience working with diverse populations that include children, adolescents, adults, geriatrics, SMI patients, and the chemically dependent.
September 16, 2026
